Is Dr Lalchand. Lab overvalued or undervalued?

As of 19 September 2025, the valuation grade for Dr Lalchand Lab has moved from expensive to attractive, indicating a significant shift in its perceived value. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE ratio of 9.97, an EV to EBITDA of 10.33, and a Price to Book Value of 1.00, all of which suggest a favorable valuation compared to its peers.
In comparison, Apollo Hospitals, which is also rated attractive, has a much higher PE ratio of 71.29 and an EV to EBITDA of 36.65, highlighting the relative undervaluation of Dr Lalchand Lab. Other peers like Max Healthcare and Fortis Health are categorized as very expensive, with PE ratios of 93.83 and 78.15, respectively. Despite a recent decline in stock price, Dr Lalchand Lab has shown a year-to-date return of 36.15%, outperforming the Sensex's 5.74%, reinforcing its attractive valuation proposition.